This systematic review evaluates the safety and efficacy of 5-aminosalicylic acid (5-ASA) for treating ulcerative colitis (UC), finding it effective in both inducing and maintaining remission in UC patients. The study showed remission rates of 50-60% depending on the dosage, with minimal side effects such as headaches and gastrointestinal disturbances.
The article titled “Association of humoral markers of inflammation and dehydroepiandrosterone sulfate or cortisol serum levels in patients with chronic inflammatory bowel disease,” published in the American Journal of Gastroenterology (1998), examined the relationship between inflammatory markers and serum levels of adrenal hormones (DHEAS and cortisol) in patients with chronic
This study explores the role of oxidative stress in the pathogenesis and treatment of inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis. It highlights how reactive oxygen species (ROS) contribute to intestinal inflammation, mucosal damage, and increased risk of colitis-associated colorectal cancer. The article reviews antioxidant therapies, including
